Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Year range
1.
Arq. neuropsiquiatr ; 72(5): 368-372, 05/2014. tab
Article in English | LILACS | ID: lil-709373

ABSTRACT

Purpose: This paper presents the initial experience with thrombolysis for acute ischaemic stroke at Hospital de Base do Distrito Federal (HBDF), Brazil, and the difficulties associated with the implementation of this treatment. Method: A retrospective study was performed using the medical records of all patients with acute stroke who were treated with intravenous alteplase in our department, between May 2011 and April 2012. Results: The thrombolytic therapy was administered to 32 patients. The mean time between the ictus and the start of stroke therapy start was 195 (60-270) minutes. Sixteen patients demonstrated a significant clinical improvement (decrease in National Institute Health Stroke Scale [NIHSS] score≥4 points in 24 hours); 6 patients were discharged with an NIHSS score of 0 and 2 demonstrated haemorrhagic transformation. Conclusions: The results of our study are similar to those reported in the literature, although we have been dealing with difficulties, such as the lack of a stroke unit. .


Introdução: O objetivo deste trabalho é apresentar a experiência inicial em trombólise para o acidente vascular encefálico isquêmico (AVC) no Hospital de Base do Distrito Federal (HBDF) e as dificuldades encontradas na implementação do serviço. Método: Foi realizado estudo retrospectivo através da análise de prontuário de todos os pacientes submetidos à terapia trombolítica no período de maio de 2011 a abril de 2012. Resultados: A terapia trombolítica foi administrada a 32 pacientes. O tempo médio do ictus até o início da terapia foi de 195 (60-270) minutos. Dezesseis pacientes apresentaram uma melhora clínica significativa (queda do National Institute Health Stroke Scale [NIHSS] maior ou igual a 4 pontos em 24 horas). Seis pacientes receberam alta com NIHSS 0. Dois pacientes apresentaram transformação hemorrágica. Conclusão: Apesar das dificuldades encontradas, como a ausência de uma Unidade de AVC, o desfecho da nossa série é semelhante aos resultados descritos na literatura. .


Subject(s)
Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Brain Ischemia/drug therapy , Fibrinolytic Agents/therapeutic use , Stroke/drug therapy , Thrombolytic Therapy/methods , Tissue Plasminogen Activator/therapeutic use , Brazil , Medical Records , Retrospective Studies , Statistics, Nonparametric , Tertiary Care Centers , Time Factors , Treatment Outcome
2.
Brasília méd ; 50(2): 118-121, nov. 2013.
Article in Portuguese | LILACS-Express | LILACS | ID: lil-694495

ABSTRACT

Vários estudos com delineamentos diferentes postulam que as estatinas podem estar relacionadas ao desenvolvimento de neuropatia periférica. Outras análises, no entanto, mostraram potencial efeito protetor dessas drogas em pacientes com neuropatia diabética. O presente trabalho tem como objetivo avaliar essa relação na literatura vigente. A revisão de vários relatos de caso, estudos populacionais e experimentos em animais não permitem afirmar se existe relação direta causal entre o uso de inibidores da hidroximetilglutaril-coenzima A e neuropatia periférica. Os benefícios das estatinas no tratamento de doenças graves tais como a aterosclerose cardiovascular e cerebral, com certeza, suplantam esse pequeno risco de acometimento de nervos periféricos.


Several studies of different designs indicate that statins could be associated with the development of peripheral neuropathy. However, other analyses have shown a potential benefit of these drugs in patients with diabetic neuropathy. Our study aims to evaluate this possible relationship comparing data from the current literature. After review of several case reports, populational studies and animal experiments, it is not possible to conclude that there is a cause-effect relationship between the use of HMG-CoA inhibitors and peripheral neuropathy. The well-established benefits of statins in the treatment of potentially severe diseases such as cerebral and cardiovascular atherosclerosis outweigh the relatively small risk of peripheral nerve involvement.

SELECTION OF CITATIONS
SEARCH DETAIL